Please wait while the page is loading...
04 October 2013
The IP Report on Listed Companies in the Pharmaceutical Industry of China, research initiated by Globe- Law and co-organized by Chinese finance website hexun.com shows that companies which rank relatively high in business income often rank not so high in the overall index indicated in the report. With respect to patent grants, in particular, companies in the pharmaceutical industry remain unbalanced.
“Many companies underperform in this indicator, six of which have no patents,” says the report, which suggests such companies increase investments in R&D and IP.
Among approximately 100 A-share listed pharmaceutical companies, IP distribution differs significantly. When judged by the five ratings on which the scores are calculated, only three companies reach a five-star level, Wang Zhengzhi, a senior partner at Globe-Law in Beijing told IPR in China, a website sponsored by China’s Ministry of Commerce.
“It proves sound capacity for research and development will help companies increase their values,” said Pan Guangcheng, vice president of Chinese Chemical and Pharmaceutical Industry Association.
